WilmerHale Advises Arsanis in Merger With X4 Pharmaceuticals
On November 27, 2018, Arsanis, Inc. (Nasdaq: ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, and privately-held X4 Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics designed to improve immune cell trafficking to treat rare diseases and cancer, announced that they have entered into a definitive merger agreement under which X4 Pharmaceuticals is expected to merge with a wholly-owned subsidiary of Arsanis in an all-stock transaction. The merger would result in a combined company operating under the X4 Pharmaceuticals name that will focus on the development and commercialization of X4’s lead product candidate, X4P-001, and the advancement of X4’s pipeline of treatments for rare diseases of the immune system and rare cancers.
WilmerHale is representing its client Arsanis in this deal, with a team led by
Jay Bothwick and
Cynthia Mazareas that also includes
Mhairi Immermann,
Andrew Langworthy,
Meghan Fay and
Sean Linnehan.
Read the full press release.
